Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Aug 21;13:1756286420947977. doi: 10.1177/1756286420947977

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), 2020

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 2. — Visual outcome categorisation of the studied eyes along the plasma exchange treatment period.

The proportions of eyes in each visual outcome category at 1 day before PE treatment (after IVMP treatment) were not significantly different from those at the onset. A significant trend of increase in visual outcome improvement was observed from the first to the fifth PE therapy as compared with the visual outcome before the PE therapy (Friedman p < 0.001). The proportions of eyes in each visual outcome category shifted significantly towards an improved distribution after the second PE therapy as compared with those at the onset, and after the third PE therapy as compared with those at 1 day before PE therapy (after IVMP treatment). The proportions in each category of visual outcome at the 1-month follow-up visit were the same as those after the fifth PE therapy. The data are presented as cumulative percentages.

*Adjusted p < 0.05 and ***adjusted p < 0.001, compared with the VA at onset; #adjusted p < 0.05, ##adjusted p < 0.01 and ###adjusted p < 0.001, compared with the VA before the PE therapy.

CF, ability to count fingers; HM, ability to perceive hand motion; IVMP, intravenous methylprednisolone; LP, light perception; NLP, no light perception; PE, plasma exchange; VA, visual acuity.